The short answer: ChondroFiller is not funded by the NHS

ChondroFiller (marketed in the UK as Liquid Cartilage™) is not available on the NHS anywhere in the United Kingdom, including Lincolnshire. It cannot be obtained through a GP referral, a standard hospital outpatient pathway, or any NHS commissioning route.

The reason is regulatory rather than clinical. NICE has not yet issued a technology appraisal for ChondroFiller in any joint indication — not for the hip, not for the knee. Because NHS commissioning for new interventions depends on a positive NICE appraisal or equivalent national guidance, the absence of one means no commissioning body can fund it. This is an access gap, not a verdict on the treatment's safety or effectiveness.

The only cartilage cell therapy that currently carries NHS funding is autologous chondrocyte implantation (ACI), approved under NICE technology appraisal TA477 in October 2017 — and that approval covers the knee only. For focal hip cartilage defects, the NHS has no equivalent funded biological repair pathway.

For patients in Lincolnshire, ChondroFiller is available exclusively through private practice.

Why the NHS has no funded pathway for hip cartilage biologics

Understanding why this gap exists requires a brief look at how treatments reach NHS patients in the first place.

For a new intervention to be routinely funded by the NHS in England, it typically needs either a positive recommendation from the National Institute for Health and Care Excellence (NICE) or an explicit NHS England commissioning policy. NICE evaluates treatments through technology appraisal programmes and, where it issues a positive recommendation, NHS trusts are legally required to fund the treatment within 90 days. Without that recommendation, individual trusts — including those serving Lincolnshire — have no commissioning authority to fund the treatment as a routine option.

ChondroFiller sits in an additional layer of complexity because it is a Class III medical device, not a pharmaceutical. NICE's standard drug appraisal pipeline does not automatically capture medical devices; devices follow a separate regulatory and health-technology-assessment process that is still maturing in the UK. CE marking confirms safety and performance standards under European device regulation, but it carries no obligation on NHS England to fund or commission a treatment.

The only biological cartilage repair therapy that has cleared the NICE appraisal route is autologous chondrocyte implantation, and — as noted above — that approval under TA477 is expressly limited to the knee joint. No equivalent appraisal exists for the hip. The structural consequence is that focal hip cartilage defects sit in a commissioning void: neither ChondroFiller nor any comparable biological scaffold has a funded NHS pathway for hip indications, not because such treatments have been assessed and declined, but because the appraisal process has not yet been applied to them in this context.

What the NHS does offer for focal hip cartilage damage

For most patients with a focal hip cartilage defect who present through NHS channels, the starting point is conservative management: a structured physiotherapy programme aimed at strengthening the muscles around the hip, activity modification to reduce joint loading, and oral analgesia or anti-inflammatory medication for symptom control. This is appropriate first-line care and helps many patients manage symptoms, though it does not restore damaged cartilage tissue.

Where conservative measures fail and the defect is surgically addressable, microfracture is the procedure most commonly available on the NHS for focal hip cartilage lesions. The technique creates small perforations in the underlying bone to stimulate a healing response, but the tissue that forms is fibrocartilage rather than the hyaline cartilage that originally lined the joint. Fibrocartilage is mechanically inferior and, in published series, microfracture carries reoperation rates of up to 41% over the medium term — a significant limitation for younger, active patients.

Autologous chondrocyte implantation is not commissioned by the NHS for the hip joint. Its NICE approval under TA477, covered in the preceding section, applies to the knee only, and hip ACI is rarely performed outside research settings in the UK.

At the far end of the spectrum, patients with end-stage cartilage loss may eventually be offered total hip replacement — a fundamentally different intervention that removes the joint surface entirely rather than preserving it.

The gap this creates is specific: patients seeking a single-stage biological repair option for a focal defect have no funded NHS route.

What ChondroFiller is and which hip patients may be suitable

ChondroFiller — sold in the UK as Liquid Cartilage™ — is an injectable Type I collagen scaffold that, once placed within the hip joint, gels within three to five minutes at body temperature. Rather than introducing live cells, it provides a temporary acellular matrix: the patient's own progenitor cells, drawn from the surrounding synovium and subchondral bone, migrate into the scaffold and begin differentiating into chondrocyte-like cells. This process — acellular matrix-induced chondrogenesis — supports the body's own repair mechanisms. It is not the same as regrowing cartilage from scratch.

The treatment is suited to isolated, focal, full-thickness cartilage defects — Grade III or IV — measuring up to 6 cm², with intact and healthy cartilage around the defect margins. In practical terms, this describes patients with discrete, contained lesions arising from injury, hip impingement (FAI), or early localised degeneration, rather than those with widespread joint-surface damage.

At Lincolnshire Hip, ChondroFiller is delivered as an ultrasound-guided outpatient injection under local anaesthesia or mild sedation. No general anaesthetic or operating theatre is required.

The treatment is not appropriate where advanced generalised hip osteoarthritis is present. A Kellgren-Lawrence Grade IV classification — indicating bone-on-bone change across the joint surface — is a contraindication, as is significant degradation of the cartilage surrounding the target defect.

Because the criteria are precise, a formal suitability assessment is the necessary first step. This typically includes a clinical review and imaging — usually MRI — to confirm defect size, lesion grade, and the condition of the surrounding cartilage before any treatment decision is made.

Clinical outcomes for ChondroFiller in the hip joint

Published multi-centre registry data offer a reasonable basis for setting expectations, though the evidence has limits worth understanding before committing to treatment.

For the hip joint specifically, studies report an average improvement of approximately 33 points in the modified Harris Hip Score — a validated measure of hip pain and function. In practical terms, a gain of that magnitude typically corresponds to a meaningful reduction in daily pain, a noticeable improvement in walking tolerance and range of movement, and reduced reliance on analgesics. Across knee, hip, and small-joint applications combined, roughly 70–85% of patients report meaningful symptom relief at three to five years in published series. The complaint rate across these series is approximately 0.06%, consistent with ChondroFiller's CE-marked Class III safety profile.

However, the hip-specific evidence base is thinner than the corresponding data for the knee. Most published studies originate from manufacturer-sponsored investigations and multi-centre registries rather than independent randomised controlled trials. No large-scale head-to-head comparison of ChondroFiller against microfracture or ACI in the hip joint has yet been published.

The honest summary is that the available evidence points to meaningful benefit for appropriately selected patients, but independent long-term trial data in the hip remain limited. Individual outcomes vary, and a thorough suitability assessment — rather than registry averages — is the appropriate basis for any personal treatment decision.

Accessing ChondroFiller privately in Lincolnshire

Lincolnshire Hip Clinic, part of the MSK Doctors group, offers ChondroFiller as an ultrasound-guided outpatient injectable scaffold pathway. No GP referral is needed to request an assessment. Clinics are accessible from Sleaford and Grantham, making the service reachable for patients across Lincolnshire and the wider East Midlands catchment.

The first step is a suitability assessment — a structured clinical review combined with MRI imaging — to confirm whether a ChondroFiller injection, a keyhole procedure, or a combined approach is appropriate for the particular defect and hip. Only once suitability is established will the treatment itself be scheduled.

ChondroFiller is privately funded. Guide costs depend on how much product the defect requires, so patients should confirm current pricing directly with the clinic before committing to a pathway. Some UK private health insurers — most commonly Bupa, Aviva, and WPA — may fund the procedure. Where insurance is in place, the treatment is billed under CCSD codes W3111 (cartilage regeneration with collagen scaffold) and W8500 (arthroscopy). Written pre-authorisation from the insurer must be obtained before the appointment; it should not be assumed retrospectively. Coverage is not guaranteed and varies by individual policy, so contacting the insurer at the earliest opportunity is advisable. Self-pay pathways are equally available for patients without applicable cover.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.